Biotechnology company Bio-Works Technologies AB announced on Monday that it has received a Letter of Intent for a EUR652,000 order of its WorkBeads affimAb, a product used in vaccine manufacturing.
This LOI highlights growing confidence in Bio-Works' role within the biopharmaceutical industry.
WorkBeads affimAb has demonstrated strong performance across various manufacturing sites, reinforcing its value in critical production settings. The order underscores customer trust in Bio-Works' quality and innovation. Bio-Works anticipates this development will further strengthen its industry partnerships.
GSK PLC announces acceptance of NDA for gepotidacin by US FDA
Sanofi in talks to sell Opella stake
Orlance receives research grant to develop Enhanced Seasonal Influenza Vaccine
MedImmune's FluMist nasal spray influenza vaccine receives US FDA approval
Gavi signs agreement with Bavarian Nordic for Mpox vaccines
Valneva seeks label extensions for chikungunya vaccine in Europe and Canada
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
OSE Immunotherapeutics initiates Phase 3 trial for cancer vaccine Tedopi
Pfizer names new Regional President for Middle East, Russia and Africa
LakeShore Biopharma names new chief executive officer
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Pfizer reports positive results for ABRYSVO RSV vaccine in immunocompromised adults